TRANSGENE
BIOTEK LIMITED
INNOVATING. FOR LIFE.

June 03, 2020

The General Manager
Department of Corporate Services – CRD,
Bombay Stock Exchange Limited (BSE),
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai 400 001.

Dear Sir

Subject: Submission of Audited Financial Results Standalone and Consolidated for the quarter and year ended 31st March 2020.

The Board of Directors at its meeting held on 03rd June 2020 have considered and approved the audited financial statement for the quarter and year ended 31st March 2020.

In term of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the following:-

1) Audited Standalone Financial Results for the quarter and year ended 31st March, 2020.
2) Audited Consolidated Financial Results for the quarter and year ended 31st March, 2020.
3) Auditors' Report on the Standalone and Consolidated Financial Results of the Company for the year ended 31st March 2020.
4) Declaration w.r.t. Audit report with unmodified opinion on Audited Financial Results for the quarter and year ended 31st March, 2020.

This is for your kind information and records.

Thanking you,

Yours faithfully,

For **TRANSGENE BIOTEK LIMITED**

DR K KOTESWARA RAO
CHAIRMAN & MANAGING DIRECTOR

Plot 69 & 70, IDA Bollaram, Sangareddy District – 502 325, Telangana, India
Ph: +91-8458-279744 Web: www.transgenebiotek.com
Email: info@transgenebiotek.com, CIN No: L85195AP1990PLC011065

TRANSGENE BIOTEK LIMITED

69 & 70, Anrich Industrial Area, Bollarum, SANGAREDDY DISTRICT.

Statement of Standalone Audited Financial Results for the Quarter and Year ended on 31st March, 2020 — In Rs.

Sl.No.	Particulars	Quarter Ended			Year Ended	
		31.03.2020	31.12.2019	31.03.2019	31.03.2020	31.03.2019
		Audited	Un-Audited	Audited	Audited	Audited
1	**Income**					
	(a) Revenue from operations (Refer note 3)	35,754	-	-	35,754	7,12,870
	(b) Other income	4,02,716	4,38,470	1,90,62,368	17,88,820	2,03,77,778
	Total Income from operations	**4,38,470**	**4,38,470**	**1,90,62,368**	**18,24,574**	**2,10,90,648**
2	**Expenses:**					
	(a) Cost of materials consumed	-3,15,955	55,732	85,879	1,47,876	3,38,525
	(b) Purchase of Stock-in-trade	-			-	
	(c) Changes in inventories of finished goods work-in-progress and stock-in-trade	-	-	-	-	-
	(d) Employee benefit expenses	7,14,691	7,14,017	8,20,121	28,95,496	24,81,867
	(e) Finance costs	7,51,533	7,51,534	6,26,374	38,05,393	25,05,496
	(f) Depreciation and amortization expenses	2,47,42,287	2,47,42,286	2,47,55,236	9,89,69,145	9,89,42,929
	(g) Others:	-				
	(i)Excise duty (Refer note 3)	-				
	(ii) Other expenses	24,15,843	7,87,947	17,96,418	56,29,036	47,48,967
	Total expenses	**2,83,08,399**	**2,70,51,516**	**2,80,84,028**	**11,14,46,946**	**10,90,17,784**
3	**Profit / (loss) before exceptional and extraordinary items and taxation (1-2)**	**-2,78,69,929**	**-2,66,13,046**	**-90,21,660**	**-10,96,22,372**	**-8,79,27,135**
4	Exceptional items	-	-	-	-	-
5	**Profit / (loss) before extraordinary items and taxation (3-4)**	**-2,78,69,929**	**-2,66,13,046**	**-90,21,660**	**-10,96,22,372**	**-8,79,27,135**
6	Extraordinary items	-	-	-	-	-
7	**Profit / (loss) before taxation (5-6)**	**-2,78,69,929**	**-2,66,13,046**	**-90,21,660**	**-10,96,22,372**	**-8,79,27,135**
8	Income tax expenses					
	(a) Current tax charge / (Credit)					
	(b) Tax relating to earlier years charge / (Credit)	-		-		-
	(c) Deferred tax charge / (Credit)					
	Total tax expenses	-	-	-	-	-
9	**Profit / (loss) for the period (7 - 8)**	**-2,78,69,929**	**-2,66,13,046**	**-90,21,660**	**-10,96,22,372**	**-8,79,27,135**
10	Other Comprehensive Income					
	(i) Items that will not be reclassified subsequently to profit or loss					
	Remeasurement of the net defined benefit liability/assets	-	-	-5,307	-	-5,005
	Change in fair value of non-current investment					
	Change in fair value of current investment					
	(ii) Items that will be reclassified subsequently to profit or loss					
	Total other comprehensive income, net of income tax	-	-	-5,307	-	-5,005
11	**Total Comprehensive income (9+10)**	**-2,78,69,929**	**-2,66,13,046**	**-90,26,967**	**-10,96,22,372**	**-8,79,32,140**
12	**Paid up Share Capital (face value of Rs. 10/- per share)**	**75,77,00,000**	**75,77,00,000**	**75,77,00,000**	**75,77,00,000**	**75,77,00,000**
13	Earnings per share of Rs. 10/- each : (Not Annualized)	7,57,70,000	7,57,70,000	7,57,70,000	7,57,70,000	7,57,70,000
	(a) Basic (Rs)	(0.4)	(0.4)	(0.1)	(1.4)	(1.2)
	(b) Diluted (Rs)	(0.4)	(0.4)	(0.1)	(1.4)	(1.2)

For TRANSGENE BIOTEK LTD

MANAGING DIRECTOR

Transgene Biotek Ltd Hyderabad

Statement of Assets and Liabilities

In Rs.

Sl. No.	Particulars	As at 31st March 2020	As at 31st March 2019
		Audited	Audited
A	**ASSETS**		
	NON-CURRENT ASSETS		
	(a) Property, plant and equipment	2,20,57,361	2,39,82,310
	(b) Assets held for Sale		
	(c) Capital work-in-progress		
	(d) Othert Intangible Assets	28,99,63,539	38,70,07,743
	(e) Financial Assets	23,02,04,250	23,02,04,250
	(i) Intangible assets under development	1,86,76,633	1,86,76,633
	(ii) Other financial assets		
	(f) Other non-current assets	9,78,749	2,94,033
	TOTAL NON - CURRENT ASSETS	**56,18,80,532**	**66,01,64,969**
	CURRENT ASSETS		
	(a) Inventories	3,84,312	3,10,911
	(b) Financial Assets		
	(i) Investments		
	(ii) Trade receivables		
	(iii) Cash and Cash equivalents	3,89,905	9,96,303
	(iv) Other financial assets		
	(v) Current tax Assets	-	5,400
	(c) Other current assets	59,59,461	50,95,980
	TOTAL CURRENT ASSETS	**67,33,678**	**64,08,594**
	TOTAL ASSETS	**56,86,14,210**	**66,65,73,562**
B	**EQUITY AND LIABILITIES**		
	EQUITY		
	(a) Equity share capital	75,77,00,000	75,77,00,000
	(b) Other equity	-60,67,30,506	-49,71,08,134
	(c) Monies Recieved against Warrants		
	TOTAL EQUITY	**15,09,69,494**	**26,05,91,866**
	LIABILITIES		
	NON-CURRENT LIABILITIES		
	(a) Financial Liabilities		
	(i) Borrowings	4,27,59,445	4,09,54,052
	(b) Other Long Term Liabilities		
	(c) Provisions	23,02,04,250	23,02,04,250
	(d) Deferred tax liabilities(net)		
	(e) Other Non Current laibilities	87,69,403	1,05,23,283
	TOTAL NON-CURRENT LIABILITIES	**28,17,33,098**	**28,16,81,585**
	CURRENT LIABILITIES		
	(a) Financial Liabilities		
	(i) Borrowings	6,05,08,298	5,03,66,109
	(ii) Trade payables	37,95,952	29,05,221
	(iii) Other financial liabilities		
	(b) Other current liabilities		
	(c) Provisions	6,99,01,787	6,98,59,527
	(d) Income tax liabilities (net)	17,05,582	11,69,253
	TOTAL CURRENT LIABILITIES	**13,59,11,619**	**12,43,00,110**
	TOTAL EQUITY AND LIABILITIES	**56,86,14,210**	**66,65,73,562**

For TRANSGENE BIOTEK LTD

MANAGING DIRECTOR

Transgene Biotek Ltd Hyderabad

Notes to the financial results:

1 Due to global lockdown, planned studies using our TrabiORAL technology on different molecules belonging to different companies have been postponed and we hope those studies will be carried out immediately after the restrictions are eased in the respective countries. However, discussions with two companies on monetization of TrabiORAL is going on an encouraging path.

2 We are in advanced stage of concluding our dialogue with one of the Central Universities for developing two novel products against Covid 19 virus, a vaccine and a therapeutic drug.

3 Following the directions from SEBI in their order dated 28th August 2019, we have submitted a report from peer reviewed auditor on the status of GDR fund recovery.

4 We have not yet received any report on the outcome of SEBI Adjudication hearing.

5 No. of Investor complaints pending at the beginning of the quarter - 0; received complaint during the quarter - 0.

6 The auditors have carried out a limited review of the above financial results and these were reviewed by the Audit committee and taken on record by the Board of Directors of the Company at their meeting held on 3rd June 2020.

By order of the Board
TRANSGENE BIOTEK LIMITED

(Dr K KOTESWARA RAO)
CHAIRMAN & MANAGING DIRECTOR

Transgene Biotek Ltd * Hyderabad *

Place: Hyderabad
Date : 03-06-2020

TRANSGENE BIOTEK LIMITED

69 & 70, Anrich Industrial Area, Bollarum, SANGAREDDY DISTRICT.

Statement of Consolidated Audited Financial Results for the Quarter and Year ended on 31st March, 2020

In Rs.

Sl.No.	Particulars	Quarter Ended			Year Ended	
		31.03.2020	31.12.2019	31.03.2019	31.03.2020	31.03.2019
		Audited	Un-Audited	Audited	Audited	Audited
1	**Income**					
	(a) Revenue from operations (Refer note 3)	35,754	-	-	35,754	7,12,870
	(b) Other income	4,02,716	4,38,470	1,90,62,368	17,88,820	2,03,77,778
	Total Income from operations	**4,38,470**	**4,38,470**	**1,90,62,368**	**18,24,574**	**2,10,90,648**
2	**Expenses:**					
	(a) Cost of materials consumed	-3,15,955	55,732	85,879	1,47,876	3,38,525
	(b) Purchase of Stock-in-trade	-			-	
	(c) Changes in inventories of finished goods work-in-progress and stock-in-trade	-	-	-	-	-
	(d) Employee benefit expenses	7,14,691	7,14,017	8,20,121	28,95,496	24,81,867
	(e) Finance costs	7,51,533	7,51,534	6,26,374	38,05,393	25,05,496
	(f) Depreciation and amortization expenses	2,47,42,287	2,47,42,286	2,47,55,236	9,89,69,145	9,89,42,929
	(g) Others:	-				
	(i)Excise duty (Refer note 3)	-				
	(ii) Other expenses	24,15,843	7,87,947	17,96,418	56,29,036	47,48,967
	Total expenses	**2,83,08,399**	**2,70,51,516**	**2,80,84,028**	**11,14,46,946**	**10,90,17,784**
3	**Profit / (loss) before exceptional and extraordinary items and taxation (1-2)**	**-2,78,69,929**	**-2,66,13,046**	**-90,21,660**	**-10,96,22,372**	**-8,79,27,135**
4	Exceptional items	-	-	-	-	-
5	**Profit / (loss) before extraordinary items and taxation (3-4)**	**-2,78,69,929**	**-2,66,13,046**	**-90,21,660**	**-10,96,22,372**	**-8,79,27,135**
6	Extraordinary items	-	-	-	-	-
7	**Profit / (loss) before taxation (5-6)**	**-2,78,69,929**	**-2,66,13,046**	**-90,21,660**	**-10,96,22,372**	**-8,79,27,135**
8	Income tax expenses					
	(a) Current tax charge / (Credit)					
	(b) Tax relating to earlier years charge / (Credit)	-		-		-
	(c) Deferred tax charge / (Credit)					
	Total tax expenses	-	-	-	-	-
9	**Profit / (loss) for the period (7 - 8)**	**-2,78,69,929**	**-2,66,13,046**	**-90,21,660**	**-10,96,22,372**	**-8,79,27,135**
10	Other Comprehensive Income					
	(i) Items that will not be reclassified subsequently to profit or loss					
	Remeasurement of the net defined benefit liability/assets	-	-	-5,307	-	-5,005
	Change in fair value of non-current investment					
	Change in fair value of current investment					
	(ii) Items that will be reclassified subsequently to profit or loss					
	Total other comprehensive income, net of income tax	-	-	-5,307	-	-5,005
11	**Total Comprehensive income (9+10)**	**-2,78,69,929**	**-2,66,13,046**	**-90,26,967**	**-10,96,22,372**	**-8,79,32,140**
12	**Paid up Share Capital (face value of Rs. 10/- per share)**	**75,77,00,000**	**75,77,00,000**	**75,77,00,000**	**75,77,00,000**	**75,77,00,000**
13	Earnings per share of Rs. 10/- each : (Not Annualized)	7,57,70,000	7,57,70,000	7,57,70,000	7,57,70,000	7,57,70,000
	(a) Basic (Rs)	(0.4)	(0.4)	(0.1)	(1.4)	(1.2)
	(b) Diluted (Rs)	(0.4)	(0.4)	(0.1)	(1.4)	(1.2)

For TRANSGENE BIOTEK LTD

MANAGING DIRECTOR

Transgene Biotek Ltd Hyderabad

Statement of Assets and Liabilities

In Rs.

Sl. No.	Particulars	As at 31st March 2020	As at 31st March 2019
		Audited	Audited
A	**ASSETS**		
	NON-CURRENT ASSETS		
	(a) Property, plant and equipment	2,20,57,361	2,39,82,309
	(b) Assets held for Sale		
	(c) Capital work-in-progress		
	(d) Othert Intangible Assets	28,99,63,539	38,70,07,743
	(e) Financial Assets	1,32,90,24,004	1,32,90,24,004
	(i) Intangible assets under development	1,86,76,633	1,86,76,633
	(ii) Other financial assets		
	(f) Other non-current assets	9,78,749	2,94,033
	TOTAL NON - CURRENT ASSETS	**1,66,07,00,286**	**1,75,89,84,722**
	CURRENT ASSETS		
	(a) Inventories	3,84,312	3,10,911
	(b) Financial Assets		
	(i) Investments		
	(ii) Trade receivables	84,460	84,460
	(iii) Cash and Cash equivalents	3,89,905	9,96,303
	(iv) Other financial assets		
	(v) Current tax Assets	-	-
	(c) Other current assets	59,59,461	51,01,380
	TOTAL CURRENT ASSETS	**68,18,138**	**64,93,054**
	TOTAL ASSETS	**1,66,75,18,424**	**1,76,54,77,775**
B	**EQUITY AND LIABILITIES**		
	EQUITY		
	(a) Equity share capital	75,77,00,000	75,77,00,000
	(b) Other equity	-43,09,62,332	-32,13,39,960
	(c) Monies Recieved against Warrants		
	TOTAL EQUITY	**32,67,37,668**	**43,63,60,040**
	LIABILITIES		
	NON-CURRENT LIABILITIES		
	(a) Financial Liabilities		
	(i) Borrowings	4,27,59,445	4,09,54,052
	(b) Other Long Term Liabilities		
	(c) Provisions	1,15,22,13,978	1,15,22,13,978
	(d) Deferred tax liabilities(net)		
	(e) Other Non Current laibilities	87,69,403	1,05,23,283
	TOTAL NON-CURRENT LIABILITIES	**1,20,37,42,826**	**1,20,36,91,313**
	CURRENT LIABILITIES		
	(a) Financial Liabilities		
	(i) Borrowings	6,05,08,298	5,03,66,109
	(ii) Trade payables	37,95,952	29,05,221
	(iii) Other financial liabilities	11,26,311	11,26,311
	(b) Other current liabilities	17,05,582	11,69,253
	(c) Provisions	6,99,01,787	6,98,59,527
	TOTAL CURRENT LIABILITIES	**13,70,37,930**	**12,54,26,421**
	TOTAL EQUITY AND LIABILITIES	**1,66,75,18,424**	**1,76,54,77,775**

For TRANSGENE BIOTEK LTD

MANAGING DIRECTOR

Transgene Biotek Ltd Hyderabad

Notes to the financial results:

1 Due to global lockdown, planned studies using our TrabiORAL technology on different molecules belonging to different companies have been postponed and we hope those studies will be carried out immediately after the restrictions are eased in the respective countries. However, discussions with two companies on monetization of TrabiORAL is going on an encouraging path.

2 We are in advanced stage of concluding our dialogue with one of the Central Universities for developing two novel products against Covid 19 virus, a vaccine and a therapeutic drug.

3 Following the directions from SEBI in their order dated 28th August 2019, we have submitted a report from peer reviewed auditor on the status of GDR fund recovery.

4 We have not yet received any report on the outcome of SEBI Adjudication hearing.

5 No. of Investor complaints pending at the beginning of the quarter - 0; received complaint during the quarter - 0.

6 The auditors have carried out a limited review of the above financial results and these were reviewed by the Audit committee and taken on record by the Board of Directors of the Company at their meeting held on 3rd June 2020.

By order of the Board
TRANSGENE BIOTEK LIMITED

Transgene Biotek Ltd Hyderabad

(Dr K Koteswara Rao)
CHAIRMAN & MANAGING DIRECTOR

Place: Hyderabad
Date : 03-06-2020

Manisha Dubey & Associates
CHARTERED ACCOUNTANTS

Auditor's report on quarterly and year to date Audited Standalone financial results for the period ended 31 March 2020 of Transgene Biotek Limited pursuant to Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
Board of Directors of
Transgene Biotek Limited

Report on the Audit of Standalone Financial Results

Opinion

We have audited the accompanying statement of quarterly financial results of TRANSGENE BIOTEK Limited for the quarter ended 31 March 2020 and the year to date standalone financial results for the period 01 April 2019 to 31 March 2020, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the year to date results:

i. are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and

ii. gives a true and fair view of the net profit/(Loss) and other financial information for the quarter ended 31 March 2020 as well as the year to date results for the period from 01 April 2019 to 31 March 2020.

Basis of Opinion

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

Management Responsibilities for the Financial Results

The Statement has been prepared on the basis of the standalone annual financial statements. The Board of Directors of the Company are responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit and other comprehensive Income of the Company and other financial Information in accordance with the applicable accounting standards prescribed under Section '133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 and 52 of the

Manisha Dubey & Associates ★ MM. No. 212664 HYD. ★ Chartered Accountants

2-4-1096, Sri Sai Digambar Tara, Nimboliadda, Kachiguda, Hyderabad - 500 027.
Cell : 9440573588, 7799001213, E-mail : manishadubey.associates@yahoo.co.in

preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error

In preparing the Statement, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either Intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.
The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

Other Matter

The Statement includes the results for the quarter ended March 31, 2020 being the balancing figure between the audited figures in respect of the full financial year ended March 31 , 2020 and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subjected to a limited review by us, as required under the Listing Regulations.

We draw attention Note 01 to the statement, which describes the business impact and uncertainties arising from COVID 19 pandemic. This is based on current facts and circumstances and may not reflect future uncertainties and events arising from the full impact of the COVID 19 pandemic.

For Manisha Dubey & Associates
Chartered Accountants
Firm's Registration No. 010114S

Manisha Dubey & Associates ★ Chartered Accountants ★ M.No. 212664 HYD.

Manisha Dubey
Proprietor
Membership No. 212664
Hyderabad - 03/06/2020
Unique Document Identification Number (UDIN) for this document is 20212664AAAAAT4815

Manisha Dubey & Associates
CHARTERED ACCOUNTANTS

Auditor's report on quarterly and year to date Audited Consolidated financial results for the period ended 31 March 2020 of Transgene Biotek Limited pursuant to Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,

Board of Directors of
Transgene Biotek Limited

Report on the Audit of Consolidated Financial Results

Opinion

We have audited the accompanying statement of quarterly financial results of **TRANSGENE BIOTEK** Limited for the quarter ended 31 March 2020 and the year to date consolidated financial results for the period 01 April 2019 to 31 March 2020, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the year to date results:

i. Includes the results of the Transgene Biotek HK Limited.
ii. are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
iii. gives a true and fair view of the net profit/(Loss) and other financial information for the quarter ended 31 March 2020 as well as the year to date results for the period from 01 April 2019 to 31 March 2020.

Basis of Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs), as specified under Section 143(10) of the Companies Act, 2013, as amended ("the Act·). Our responsibilities under those Standards are further described in the • Auditor's Responsibilities for the Audit of the Consolidated Financial Results• section of our report. We are independent of the Group, its associates and joint venture in accordance with the 'Code of Ethics' issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us and other auditors in terms of their reports referred to in ·other Matter" paragraph below, is sufficient and appropriate to provide a basis for our opinion.

Management Responsibilities for the Financial Results

The Statement has been prepared on the basis of the consolidated annual financial statements.The Holding Company's Board of Directors are responsible for the preparation and presentation of the Statement that give a true and fair view of the net profit and other comprehensive Income and other

2-4-1096, Sri Sai Digambar Tara, Nimboliadda, Kachiguda, Hyderabad - 500 027.
Cell : 9440573588, 7799001213, E-mail : manishadubey.associates@yahoo.co.in

financial information of the Group including its associates and joint venture in accordance with the applicable accounting standards prescribed under section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 and 52 of the Listing Regulations. The respective Board of Directors of the companies Included in the Group and of its associates and joint venture are responsible for maintenance of adequate accounting records In accordance with the provisions of the Act for safeguarding of the assets of the Group and its associates and joint venture and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement. whether due to fraud or error, which have been used for the purpose of preparation of the Statement by the Directors of the Holding Company, as aforesaid.

In preparing the Statement, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either Intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so. The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

Other Matter

The accompanying Statement includes the audited financial statements and other financial information, in respect of 1 subsidiary (the transaction are nil of the said subsidiary for the said FY 2019-20).

Our opinion on the Statement is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors and the financial information certified by management.

The Statement includes the results for the quarter ended March 31, 2020 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2020 and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subjected to a limited review by us, as required under the Listing Regulations.



We draw attention Note 01 to the statement, which describes the business impact and uncertainties arising from COVID 19 pandemic. This is based on current facts and circumstances and may not reflect future uncertainties and events arising from the full impact of the COVID 19 pandemic.

For Mansiha Dubey & Associates
Chartered Accountants
Firm's Registration No.010145S



Mansiha Dubey
Proprietor
Membership No. 212664
Hyderabad - 03/06/2020
Unique Document Identification Number (UDIN) for this document is 20212664AAAAAT4815

TRANSGENE
BIOTEK LIMITED
INNOVATING. FOR LIFE.

June 03, 2020

The General Manager
Department of Corporate Services – CRD,
Bombay Stock Exchange Limited (BSE),
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai 400 001.

Dear Sir

Subject: Declaration pursuant to Regulations 33(3)(d) and 30(3) of SEBI (Listing obligations and Disclosure Requirement), Regulations, 2015.

I, Dr K Koteswara Rao, Chairman & Managing Director of M/s Transgene Biotek Limited hereby declare that Manisha Dubey & Associates, Chartered Accountants of the Company (Membership No:212664) have issued unmodified opinion on Annual Audited Financial Results for the quarter and year ended 31st March 2020.

This declaration is given in compliance to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended vide its Circular No. CIR/CFD/CMD/56/2016 dated May 27, 2016.

In compliance to the advisory dated May 20, 2020 on disclosure of material impact of CoVID-19 pandemic under Regulation 30(3) specified in Para B of Part A of Schedule III of LODR, we wish to state that the company's operations were adversely impacted by having to stop all activities from the second half of March till today. Further, such global lockdown has also impacted with the postponement of the planned in-vivo studies on the molecules belonging to different companies in different countries formulated on TrabiORAL platform.

This is for your kind information and records.

Thanking you,

Yours faithfully,

For **TRANSGENE BIOTEK LIMITED**

DR K KOTESWARA RAO
CHAIRMAN & MANAGING DIRECTOR

Plot 69 & 70, IDA Bollaram, Sangareddy District – 502 325, Telangana, India
Ph: +91-8458-279744 Web: www.transgenebiotek.com
Email: info@transgenebiotek.com, CIN No: L85195AP1990PLC011065